The pharmacological rationale for treating vascular dementia with galantamine (Reminyl)
- PMID: 11406923
The pharmacological rationale for treating vascular dementia with galantamine (Reminyl)
Abstract
There is considerable evidence indicating that, as in Alzheimer's disease, the central cholinergic system is impaired in vascular dementia (VaD). Using lessons learned from Alzheimer's disease research, it has been proposed that enhancement of the cholinergic system is a rational approach to treating the symptoms of VaD. Galantamine's dual mode of action may provide a greater chance of success in treating patients with Alzheimer's disease through enhanced efficacy on the cognitive, functional and behavioural aspects of dementia. Trials are currently underway to see if this broad spectrum of efficacy extends to patients with Alzheimer's disease with cerebrovascular disease ('mixed' dementia) or VaD, as well as other conditions, and the results are eagerly awaited.
Similar articles
-
Galantamine: use in Alzheimer's disease and related disorders.Expert Rev Neurother. 2004 Mar;4(2):153-63. doi: 10.1586/14737175.4.2.153. Expert Rev Neurother. 2004. PMID: 15853556 Review.
-
Galantamine: a review of its use in Alzheimer's disease and vascular dementia.Int J Clin Pract. 2003 Apr;57(3):219-23. Int J Clin Pract. 2003. PMID: 12723727 Review.
-
Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.J Clin Pharmacol. 2006 Jul;46(7 Suppl 1):17S-26S. doi: 10.1177/0091270006288735. J Clin Pharmacol. 2006. PMID: 16809811 Review.
-
Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.J Neurol Sci. 2004 Nov 15;226(1-2):63-6. doi: 10.1016/j.jns.2004.09.018. J Neurol Sci. 2004. PMID: 15537522 Review.
-
Update on Alzheimer drugs (galantamine).Neurologist. 2003 Sep;9(5):235-40. doi: 10.1097/01.nrl.0000087722.46430.c4. Neurologist. 2003. PMID: 12971834 Review.
Cited by
-
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.CNS Drug Rev. 2002 Summer;8(2):159-76. doi: 10.1111/j.1527-3458.2002.tb00221.x. CNS Drug Rev. 2002. PMID: 12177686 Free PMC article. Review.
-
Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression.J Psychiatry Neurosci. 2003 May;28(3):197-209. J Psychiatry Neurosci. 2003. PMID: 12790160 Free PMC article.
-
Potential Role of Honey in Learning and Memory.Med Sci (Basel). 2015 Apr 9;3(2):3-15. doi: 10.3390/medsci3020003. Med Sci (Basel). 2015. PMID: 29083387 Free PMC article. Review.